Trial Profile
20150288 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Amgen
- 01 Sep 2022 Results of consolidation with blinatumomab in patients with newly diagnosed high-risk DLBCL,published in the Leukemia and Lymphoma
- 12 Mar 2020 Cyclophosphamide, Dexamethasone, Doxorubicin, Prednisone, Rituximab, Vincristine have been officially added to the treatments section as a part of the study protocol. A safety follow-up for 30 days and a long-term follow-up of up to 8 months for a maximum 1 year have been introduced into the study.
- 06 Nov 2019 Results assessing efficacy and safety of blinatumomab after first line rituximab chemotherapy for patients with newly diagnosed, released in 61st Annual Meeting and Exposition of the American Society of Hematology